Balaglitazone

Research use only, not for human use.

Balaglitazone is a selective peroxisome proliferator-activated receptor (PPARγ) partial agonist with an EC50 value of 1.351 μM for human PPARγ.

Balaglitazone is a selective partial PPARγ agonist with an EC50 of 1.351 μM for human PPARγ.

Balaglitazone is a selective partial PPARγ agonist with an EC50 of 1.351 μM. Balaglitazone (5-100 μM) has equal cytotoxicity towards K562 and K562/DOX cells. Balaglitazone decreases doxorubicin cytotoxicity in K562 and K562/DOX cells, with IC50s of 0.117 μM and 0.53 μM, respectively. Balaglitazone reverses multidrug resistance (MDR) in K562/DOX cells. Balaglitazone (25 μM) increases Rh123 accumulation in K562/DOX cells, but does not increases MFI in K562 cells. Balaglitazone downregulates P-gp expression in K562/DOX cells, and such effects are via upregulation of PTEN in K562/DOX cells, and be abolished by PTEN inhibition.

Balaglitazone (3 mg/kg, p.o.) shows antihyperglycaemic activity in fully diabetic and insulin resistant db/db mice, and is more potent than the full PPARγ agonist rosiglitazone. Balaglitazone (10 mg/kg, p.o.) suppresses overall glucose, decreases insulin levels, and increases bodyweight in male diet-induced obese rats, and such effects are equal to that of 30 mg/kg pioglitazone.

——

Metabolic Enzyme/Protease

PPAR

PPAR

——

——

199113-98-9

395.43

C20H17N3O4S

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (252.89 mM; Ultrasonic )

Cn1c(COc2ccc(CC3SC(=O)NC3=O)cc2)nc2ccccc2c1=O

——

(-20℃)

With Ice Pack

≥ 2 years